Methods and compositions for detecting a drug resistant EGFR mutant
US8501413B2 · kind B2 · utility
3Cited by
2References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 17, 2011 |
| Grant date | Aug 6, 2013 |
| Priority date | — |
| Expiry date | Nov 23, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Development of acquired resistance to the therapeutic effects of an epidermal growth factor (EGFR) tyrosine kinase inhibitor in a patient that is suffering from a cancer is predicted by:
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.